AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development
Happy readings on this article in Vaccine Insights, based on an interview with two of the AstriVax co-founders Kai Dallmeier and Hanne Callewaert, describing the advantages of the Plasmid Launching Live Attenuated Virus (PLLAV) technology that is being further developed at AstriVax. Published by Charlotte Barker, editor in Vaccine Insights.
Read the testimonial of AstriVax CEO Hanne Callewaert in the BVA | Belgian Venture Capital & Private Equity Association
Nice article on AstriVax in ‘De Tijd’ with our CEO Hanne Callewaert and PMV. Thank you Bart De Taeye and Filip Goossens from PMV to highlight the importance of a strong team as necessary ingredient for a successful start-up.
AstriVax receives the European Lifestar Award for ‘Seed-Stage Finance Raise of the Year 2022’ by LSX – partnering for Life Science eXecutives
AstriVax receives the “Best Pitch Award” at Immunity for Health from Flanders Vaccine, sponsored by the Biotech Innovation Procurement Platform (BIPP)
AstriVax: thermostable, plug-and-play vaccines using plasmids – Biocentury
Dr. Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax
